Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

AV-65, a Novel Inhibitor of the Wnt/β-Catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells.

Hisayuki Yao, MD, Eishi Ashihara, MD, PhD, Rina Nagao, Shinya Kimura, MD, PhD, Hideyo Hirai, MD, PhD, Jeffrey W Strovel, PhD, Janak Padia, PhD, Wieslaw M Cholody, PhD, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2866.

https://doi.org/10.1182/blood.V114.22.2866.2866

Published: 2009

Journal Articles

Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells.

Rina Nagao, Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Hisayuki Yao, MD, Miki Takeuchi, MD, Asumi Yokota, MMSc, Ruriko Tanaka, MMSc, Hideyo Hirai, MD, PhD, Jeffrey W Strovel, Janak Padia, Wieslaw M Cholody, Taira Maekawa, MD, PhD

Blood (2009) 114 (22): 2184.

https://doi.org/10.1182/blood.V114.22.2184.2184

Published: 2009

Journal Articles

A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation.

Rina Nagao, Shinya Kimura, MD, PhD, Eishi Ashihara, MD, PhD, Miki Takeuchi, MD, Ruriko Tanaka, MMSc, Asumi Yokota, MMSc, Hisayuki Yao, MD, Jeffrey W Strovel, Wieslaw M Cholody, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 1081.

https://doi.org/10.1182/blood.V112.11.1081.1081

Published: 2008

Journal Articles

In Vitro Characterization of Wnt/β-Catenin Pathway Inhibition in Multiple Myeloma Cell Lines Using a Novel Class of Small Molecules.

Jeffrey W. Strovel, PhD, Tammy Lawrence, B.S., Pachai Natarajan, M.S., Stephen Glanowski, Ph.D., Irina Lonskaya, Ph.D., Zoe Weaver, Ph.D., Janka Padia, Ph.D., Jeffrey W. Watthey, Ph.D., Wieslaw M. Cholody, Ph.D., J. Michael Hamilton, M.D., David K. Bol, Ph.D., Stephen K. Horrigan, Ph.D.

Blood (2007) 110 (11): 2523.

https://doi.org/10.1182/blood.V110.11.2523.2523

Published: 2007

Journal Articles

Clinical-Biomarker Correlations in Adult AML Patients in a Phase I Trial of AVN944 Support Observations of Clinical Effect and Provide Hypotheses for Patient Selection Criteria for Further Clinical Trials.

Rebecca B. Klisovic, MD, Steven Coutre, MD, Tibor J. Kovacsovics, MD, Hagop M. Kantarjiam, MD, Guido J. Tricot, MD, Jeffrey W. Strovel, PhD, Thomas Genna, RhP, David K. Bol, PhD, Michael Hamilton, MD, Beverly S. Mitchell, MD

Blood (2007) 110 (11): 896.

https://doi.org/10.1182/blood.V110.11.896.896

Published: 2007

Journal Articles

Genetic and Biochemical Biomarkers of IMPDH Inhibition in Phase I Dose Escalation of AVN-944 for Hematologic Malignancies.

Jeffrey W. Strovel, PhD, Marion Chakiath, M.S, Pachai Natarajan, M.S., Tammy Lawrence, M.S., Karina M. Zuck, Ph.D., Lenore Urbani, Ph.D., Beverly S. Mitchell, M.D., David K. Bol, Ph.D.

Blood (2006) 108 (11): 2590.

https://doi.org/10.1182/blood.V108.11.2590.2590

Published: 2006

NARROW

AV-65, a Novel Inhibitor of the Wnt/β-Catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells.

Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells.

A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation.

In Vitro Characterization of Wnt/β-Catenin Pathway Inhibition in Multiple Myeloma Cell Lines Using a Novel Class of Small Molecules.

Clinical-Biomarker Correlations in Adult AML Patients in a Phase I Trial of AVN944 Support Observations of Clinical Effect and Provide Hypotheses for Patient Selection Criteria for Further Clinical Trials.

Genetic and Biochemical Biomarkers of IMPDH Inhibition in Phase I Dose Escalation of AVN-944 for Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

AV-65, a Novel Inhibitor of the Wnt/β-Catenin Signaling Pathway, Inhibits the Proliferation of Myeloma Cells.

Inhibition of Wnt/β-Catenin Signaling by AV65 Treatment Caused Cell Cycle Arrest and Induced Caspase-Independent or -Dependent Apoptosis in CML Cells.

A Novel β-catenin Inhibitor, AV65 Suppresses the Growth of CML Cell Lines Which Acquire Imatinib-Resistance Because of Abl Kinase Domain Mutations Including T315I and Hypoxia-Adaptation.

In Vitro Characterization of Wnt/β-Catenin Pathway Inhibition in Multiple Myeloma Cell Lines Using a Novel Class of Small Molecules.

Clinical-Biomarker Correlations in Adult AML Patients in a Phase I Trial of AVN944 Support Observations of Clinical Effect and Provide Hypotheses for Patient Selection Criteria for Further Clinical Trials.

Genetic and Biochemical Biomarkers of IMPDH Inhibition in Phase I Dose Escalation of AVN-944 for Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only